Anke Bio (Shanghai) Innovation Institute Unveiled to Empower High-Quality Development of the Biopharmaceutical Industry

11Month27Day,Anhui Biopharmaceutical EnterpriseANKEBIOEngineering (Group) Co., Ltd.Shanghai Zhangjiang Science City Officially UnveiledTwo Major Institutions——ANKEBIO (Shanghai) Innovation Research Institute and Shanghai Anke Huaze Pharmaceutical Co., Ltd.This move represents a critical step in the company’s transformation and upgrading of its R&D system, as well as in the integration and refinement of its industrial chain. It not only demonstrates the company’s strategic intent to increase investment in frontier technologies and enhance its core competitiveness, but also reflects the development trend of domestic biopharmaceutical enterprises focusing on innovation in the biopharmaceutical sector.

Amid increasingly fierce global competition in the pharmaceutical industry, R&D and innovation capabilities have become the cornerstone of enterprises’ long-term development. It is reported that the newly unveiled ANKEBIO (Shanghai) Innovation Research Institute is positioned as a strategic platform for the ANKEBIO Group to explore frontier areas in biomedicine and conduct core technology development. The institute will systematically establish R&D systems for innovative biologics, peptide drugs, small nucleic acid drugs, and modern traditional Chinese medicine.

Located in the core area of Shanghai Zhangjiang Science City, a hub for high-end talent and a mature industrial ecosystem, the Research Institute aims to leverage its geographical advantages and international resources. It focuses on cutting-edge fields such as antibody drugs, Antibody-Drug Conjugates (ADCs), cellular immunotherapy, and gene therapy, serving as an innovation engine to drive the future development of ANKEBIO.

It is reported that ANKEBIO is a national pilot enterprise for innovation and a national demonstration enterprise for technological innovation. The company hosts key technical platforms, including a National Enterprise Technology Center and the National-Local Joint Engineering Research Center for Precision Oncology Technologies and Products. The establishment of its Innovation Institute not only serves as a vital “incubator” for ANKEBIO’s core technologies but also strives to enhance the scientific rigor and systematic nature of its R&D processes. This initiative provides sustained momentum for the steady advancement of its R&D pipeline, shortens development cycles, and accelerates clinical research and commercialization. Furthermore, it reinforces ANKEBIO’s diversified and integrated R&D ecosystem—combining independent R&D, collaborative R&D, and equity investment—to more effectively engage with top-tier research institutions and cutting-edge scientific projects, thereby gradually achieving a critical transition from technological following to parallel development and ultimately to technological leadership.

In addition, Shanghai Anke Huaze Pharmaceutical Co., Ltd., which was concurrently unveiled, will serve as the core operating entity for ANKEBIO’s peptide business. It will inherit the expertise accumulated by Shanghai Suhao Yiming Pharmaceutical Co., Ltd., a former wholly-owned subsidiary of ANKEBIO, in the field of peptide active pharmaceutical ingredients (APIs), and synergize with Anhui Anke Huaze Pharmaceutical in formulation development and market promotion. This integration aims to establish a complete industrial chain for the peptide business, encompassing “API production–formulation development–market promotion.” Industry analysts point out that this model will not only help strengthen supply chain stability and quality control capabilities but also build a comprehensive translation system for peptide drugs from concept design to product commercialization, thereby enhancing ANKEBIO’s overall competitiveness in this niche sector.

Currently, the global pharmaceutical industry is undergoing profound transformation, making ANKEBIO’s strategic layout a representative case. This move signifies not only an upgrade of the company’s own R&D system and industrial chain but also serves as a microcosm of Chinese pharmaceutical enterprises building autonomous and controllable industrial ecosystems, deepening their strategic layouts for innovative drugs, and pursuing high-quality development in global competition. It represents a proactive practice by domestic pharmaceutical companies to compete in the core arena of global innovative drug development.